Biocitech, France, June 11, 2007 - Cellectis S.A., the rational genome engineering company developing a new range of products for the custom rewriting of DNA sequences in the research, healthcare and industrial sectors, today announced that a Board of Appeal of the European Patent Office (“EPO”) has just dismissed the appeal filed by Johns Hopkins University against the decision of the Opposition division concerning their European Patent licensed to Sangamo Biosciences, Inc. (“Sangamo”); said Patent having been revoked in May 2005 by the Opposition division. The Patent No EP 0682699 entitled “Functional Domains In Flavobacterium Okeanokoites (FOKI) Restriction Endonuclease” was granted on May 7, 2003, and formed the basis of Regional Phase patents in France, Germany, the United Kingdom, Ireland and Switzerland. The granted patent’s claims covered technologies used in Sangamo’s programs in targeted recombination and gene correction.
